Detalhe da pesquisa
1.
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Ann Hematol
; 100(4): 969-978, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33594448
2.
R-BEAM versus Reduced-Intensity Conditioning Regimens in Patients Undergoing Allogeneic Stem Cell Transplantation for Relapsed Refractory Diffuse Large B Cell Lymphoma.
Biol Blood Marrow Transplant
; 26(4): 683-690, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31682979
3.
Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts.
Am J Hematol
; 95(2): 198-204, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31691333
4.
Liver Graft-Versus-Host Disease is associated with poor survival among allogeneic hematopoietic stem cell transplant recipients.
Am J Hematol
; 94(10): 1072-1080, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31292984
5.
Fluoroquinolone prophylaxis in autologous hematopoietic stem cell transplant recipients.
Support Care Cancer
; 25(8): 2593-2601, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28365897
6.
Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.
Biol Blood Marrow Transplant
; 22(5): 869-78, 2016 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-26827660
7.
Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation.
Am J Hematol
; 91(9): E341-7, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27238902
8.
Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
Biol Blood Marrow Transplant
; 21(1): 159-64, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25445637
9.
High incidence of severe acute graft-versus-host disease with tacrolimus and mycophenolate mofetil in a large cohort of related and unrelated allogeneic transplantation patients.
Biol Blood Marrow Transplant
; 20(7): 979-85, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24709007
10.
Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
J Clin Apher
; 29(6): 293-8, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24700728
11.
A phase I dose-escalation trial of high-dose melphalan with palifermin for cytoprotection followed by autologous stem cell transplantation for patients with multiple myeloma with normal renal function.
Biol Blood Marrow Transplant
; 19(1): 56-61, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22892551
12.
CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
Biol Blood Marrow Transplant
; 19(6): 925-33, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23529012
13.
A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation.
Am J Hematol
; 93(4): E96-E98, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29318650
14.
Evaluating the effects of lenalidomide induction therapy on peripheral stem cells collection in patients undergoing autologous stem cell transplant for multiple myeloma.
Support Care Cancer
; 21(9): 2437-42, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23591714
15.
Impact of Pre-transplant Induction Therapy on Outcomes of Patients Who Undergo Autologous Stem Cell Transplantation for Mantle Cell Lymphoma in First Complete Remission.
Hematol Oncol Stem Cell Ther
; 16(2): 154-157, 2023 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34425096
16.
Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission.
Leuk Lymphoma
; 64(7): 1285-1294, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37154379
17.
Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant
; 18(11): 1734-44, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22710143
18.
Melphalan 180 mg/m2 can be safely administered as conditioning regimen before an autologous stem cell transplantation (ASCT) in multiple myeloma patients with creatinine clearance 60 mL/min/1.73 m2 or lower with use of palifermin for cytoprotection: results of a phase I trial.
Biol Blood Marrow Transplant
; 18(9): 1455-61, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22453252
19.
Aprepitant for prevention of nausea and vomiting secondary to high-dose cyclophosphamide administered to patients undergoing autologous peripheral blood stem cells mobilization: a phase II trial.
Support Care Cancer
; 20(10): 2363-9, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22193771
20.
Role of High-Dose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review.
J Oncol
; 2022: 3472324, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36213836